Last reviewed · How we verify
Chronic pain
Approved treatments
- Ultram · Janssen
- Subutex · Indivior
Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors. - Naltrexon · Institute of Liver and Biliary Sciences, India
- Subutex · Purdue Pharma Lp
Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist. - MS Contin · Generic (multiple manufacturers)
The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids. - Dolobid
- Duramorph Pf · Pfizer
Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body. - Opana Er · Endo
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic pain patent landscape — cliff calendar, originator estates, attackable patents
- Chronic pain treatment landscape brief
- Chronic pain treatment updates RSS
Frequently asked questions about Chronic pain
What drugs treat Chronic pain?
Tracked treatments include Ultram, Subutex, Naltrexon, MS Contin, Dolobid, Duramorph Pf, Opana Er.
What is the treatment for Chronic pain?
Standard treatment for Chronic pain includes Ultram, Subutex, Naltrexon, MS Contin, Dolobid. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic pain patent cliff · Chronic pain CI report
- Treatment: Ultram · Janssen
- Treatment: Subutex · Indivior
- Treatment: Naltrexon · Institute of Liver and Biliary Sciences, India
- Treatment: Subutex · Purdue Pharma Lp
- Treatment: MS Contin · Generic (multiple manufacturers)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing